- Keryx (KERX) has come back under the magnifying glass at PropThink. We hosted Dr. Scott Chambers, a patent attorney and former USPTO staff, on a conference call this week with our subscribers. The call cleared up a lot of unanswered questions about Zerenex’s IP protection, and our readers who were involved at the beginning of the week pulled in a 15% return as the patent concerns were a sensitive issue, and our call generated interest. We’ll be releasing the transcript to subscribers next week — those interested in getting a first look can sign up here. There are a lot of reasons to own this name in the long-run, but for the traders out there, three events in the next six months are essentially de-risked.
- Last week, we suggested that catalysts through the rest of the year would drive ASTX, and beginning a position on any weakness made sense. Already that trade has netted 18% for readers who bought the dip at the end of last week.
- InVivo (NVIV) is up 34% since Mr. Napodano covered the name in mid-March, and his thesis has been validated. The company received a HUD designation and the FDA granted approval for its IDE application this week.
- BioLife Solutions (BLFS) is a top pick for Mr. Deryugin, and he believes that the company’s OTC listing shouldn’t worry long-term investors. The company is demonstrating growth on multiple levels and insider ownership suggests commitment to the business.
- Sarepta was a hot item this week as lead competitor GlaxoSmithKline presented clinical trial results for its own DMD drug, drisapersen. Everyone’s got an opinion, but whether Sarepta files for an accelerated approval or not, we think that having a starter position in advance is the best way for long-term investors to be involved now. Our readers are up 27% since we started following the name.
- PropThink subscribers picked up some XNPT on Friday when the stock dipped on arguably immaterial news – Horizant manufacturing has some kinks, but the asset is not a key piece of XNPT’s valuation; the stock recovered by the close. Here’s the trade.
- With data due at ASCO in two months and an interesting ADC development platform, IMMU has potential as a comparatively cheap oncology holding. The key catalyst, Phase III SLE data for lead candidate Epratuzumab, is next year for the long-term investors.
- Mr. Napodano outlined the bull thesis on DARA Bio, and, in fact, took a little heat for his coverage (you can read Jason’s brief rebuttal on his blog). Admittedly a risky holding, it’s all about execution at the specialty pharma company, and the stock is undoubtedly undervalued if the company’s products — two approved — pan out commercially.
